139 related articles for article (PubMed ID: 8293411)
1. Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine.
Wu LT; Averbuch SD; Ball DW; de Bustros A; Baylin SB; McGuire WP
Cancer; 1994 Jan; 73(2):432-6. PubMed ID: 8293411
[TBL] [Abstract][Full Text] [Related]
2. Treatment of advanced medullary thyroid carcinoma with a combination of cyclophosphamide, vincristine, and dacarbazine: a single-center experience.
Deutschbein T; Matuszczyk A; Moeller LC; Unger N; Yuece A; Lahner H; Mann K; Petersenn S
Exp Clin Endocrinol Diabetes; 2011 Oct; 119(9):540-3. PubMed ID: 21667440
[TBL] [Abstract][Full Text] [Related]
3. Treatment of advanced medullary thyroid carcinoma with a combination of recombinant interferon alpha-2b and octreotide.
Lupoli G; Cascone E; Arlotta F; Vitale G; Celentano L; Salvatore M; Lombardi G
Cancer; 1996 Sep; 78(5):1114-8. PubMed ID: 8780551
[TBL] [Abstract][Full Text] [Related]
4. Chemotherapy with dacarbazine and 5-fluorouracil in advanced medullary thyroid cancer.
Orlandi F; Caraci P; Berruti A; Puligheddu B; Pivano G; Dogliotti L; Angeli A
Ann Oncol; 1994 Oct; 5(8):763-5. PubMed ID: 7826911
[TBL] [Abstract][Full Text] [Related]
5. Early changes in carcinoembryonic antigen but not in calcitonin levels are correlated with the progression-free survival in medullary thyroid carcinoma patients treated with cytotoxic chemotherapy.
Hajje G; Borget I; Leboulleux S; Chougnet C; Al Ghuzlan A; Mirghani H; Caramella C; Hartl D; Schlumberger M; Baudin E
Eur J Endocrinol; 2013 Feb; 168(2):113-8. PubMed ID: 23093698
[TBL] [Abstract][Full Text] [Related]
6. Combining radioimmunotherapy and chemotherapy for treatment of medullary thyroid carcinoma: effectiveness of dacarbazine.
Stein R; Chen S; Reed L; Richel H; Goldenberg DM
Cancer; 2002 Jan; 94(1):51-61. PubMed ID: 11815960
[TBL] [Abstract][Full Text] [Related]
7. Improved treatment of medullary thyroid cancer in a nude mouse model by combined radioimmunochemotherapy: doxorubicin potentiates the therapeutic efficacy of radiolabeled antibodies in a radioresistant tumor type.
Behr TM; Wulst E; Radetzky S; Blumenthal RD; Dunn RM; Gratz S; Rave-Fränk M; Schmidberger H; Raue F; Becker W
Cancer Res; 1997 Dec; 57(23):5309-19. PubMed ID: 9393755
[TBL] [Abstract][Full Text] [Related]
8. A humanized monoclonal antibody to carcinoembryonic antigen, labetuzumab, inhibits tumor growth and sensitizes human medullary thyroid cancer xenografts to dacarbazine chemotherapy.
Stein R; Goldenberg DM
Mol Cancer Ther; 2004 Dec; 3(12):1559-64. PubMed ID: 15634649
[TBL] [Abstract][Full Text] [Related]
9. Treatment of advanced medullary thyroid cancer with an alternating combination of doxorubicin-streptozocin and 5 FU-dacarbazine. Groupe d'Etude des Tumeurs à Calcitonine (GETC).
Nocera M; Baudin E; Pellegriti G; Cailleux AF; Mechelany-Corone C; Schlumberger M
Br J Cancer; 2000 Sep; 83(6):715-8. PubMed ID: 10952773
[TBL] [Abstract][Full Text] [Related]
10. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine.
Averbuch SD; Steakley CS; Young RC; Gelmann EP; Goldstein DS; Stull R; Keiser HR
Ann Intern Med; 1988 Aug; 109(4):267-73. PubMed ID: 3395037
[TBL] [Abstract][Full Text] [Related]
11. Treatment of malignant phaeochromocytoma with a combination of cyclophosphamide, vincristine and dacarbazine: own experience and overview of the contemporary literature.
Deutschbein T; Fassnacht M; Weismann D; Reincke M; Mann K; Petersenn S
Clin Endocrinol (Oxf); 2015 Jan; 82(1):84-90. PubMed ID: 25143180
[TBL] [Abstract][Full Text] [Related]
12. Metastatic medullary thyroid carcinoma. Complete response to combination chemotherapy with dacarbazine and 5-fluorouracil.
Petursson SR
Cancer; 1988 Nov; 62(9):1899-903. PubMed ID: 3167804
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II trial of (131)I-MN-14F(ab)2 anti-carcinoembryonic antigen monoclonal antibody in the treatment of patients with metastatic medullary thyroid carcinoma.
Juweid ME; Hajjar G; Swayne LC; Sharkey RM; Suleiman S; Herskovic T; Pereira M; Rubin AD; Goldenberg DM
Cancer; 1999 Apr; 85(8):1828-42. PubMed ID: 10223579
[TBL] [Abstract][Full Text] [Related]
14. Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients.
Huang H; Abraham J; Hung E; Averbuch S; Merino M; Steinberg SM; Pacak K; Fojo T
Cancer; 2008 Oct; 113(8):2020-8. PubMed ID: 18780317
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic value of selected biochemical markers in the detection of recurrence of medullary thyroid cancer - comparison of calcitonin, procalcitonin, chromogranin A, and carcinoembryonic antigen.
Woliński K; Kaznowski J; Klimowicz A; Maciejewski A; Łapińska-Cwojdzińska D; Gurgul E; Car AD; Fichna M; Gut P; Gryczyńska M; Ruchała M
Endokrynol Pol; 2017; 68(4):434-437. PubMed ID: 28585679
[TBL] [Abstract][Full Text] [Related]
16. [Combination therapy with adriamycin, cisplatin and vindesine in C cell carcinoma of the thyroid].
Scherübl H; Raue F; Ziegler R
Onkologie; 1990 Jun; 13(3):198-202. PubMed ID: 2204006
[TBL] [Abstract][Full Text] [Related]
17. Treatment of advanced medullary thyroid cancer with an alternating combination of 5 FU-streptozocin and 5 FU-dacarbazine. The Groupe d'Etude des Tumeurs a Calcitonine (GETC).
Schlumberger M; Abdelmoumene N; Delisle MJ; Couette JE
Br J Cancer; 1995 Feb; 71(2):363-5. PubMed ID: 7530987
[TBL] [Abstract][Full Text] [Related]
18. Medullary thyroid carcinoma: including MEN 2A and MEN 2B syndromes.
Quayle FJ; Moley JF
J Surg Oncol; 2005 Mar; 89(3):122-9. PubMed ID: 15719378
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin analogs in the treatment of medullary thyroid carcinoma.
Díez JJ; Iglesias P
J Endocrinol Invest; 2002 Oct; 25(9):773-8. PubMed ID: 12398235
[TBL] [Abstract][Full Text] [Related]
20. Two cases of malignant pheochromocytoma treated with cyclophosphamide, vincristine and dacarbazine in a combined chemotherapy.
Noshiro T; Honma H; Shimizu K; Kusakari T; Watanabe T; Akama H; Shibukawa S; Miura W; Abe K; Miura Y
Endocr J; 1996 Jun; 43(3):279-84. PubMed ID: 8886621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
